TGFα-PE38 Enhances Cytotoxic T-lymphocyte Killing of Breast Cancer Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2014 Jun 17

PMID 24932299

Citations 3

Authors

Stephen E Wright

Kathleen A Rewers-Felkins

Imelda Quinlin

Nazrul I Chowdhury

Jewel Ahmed

Paul W Eldridge

Sanjay K Srivastava

Ira Pastan

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to determine whether the combination of two modalities of immunotherapy, targeting two different tumor antigens, may be feasible and non-toxic, yet enhance the killing of a human breast cancer cell line. The first modality was tumor growth factor α- exotoxin 38 (TGFα-PE38), which specifically targets and kills tumor cells that express the epidermal growth factor receptor. The second modality was mucin-1 (MUC1)-specific cytotoxic T lymphocytes (CTLs), generated by MUC1 stimulation of peripheral blood mononuclear cells, to target the human breast cancer cell line, MCF7. TGFα-PE38 exhibited specific lysis of the MCF7 cells in a concentration- and time-dependent manner. TGFα-PE38 did not kill the normal hematopoietic stem cells or CTLs. Furthermore, TGFα-PE38 was not inhibitory for the growth or differentiation of the normal human hematopoietic stem cells into erythroid and myeloid colonies. In addition, TGFα-PE38 did not inhibit the killing function of CTLs, either when preincubated or co-incubated with CTLs. Finally, therapeutic enhancement was observed, in that TGFα-PE38 and CTLs were additive in the specific lysis of the MCF7 cells. These two modalities of immunotherapy may be beneficial for humans with breast cancer with or without other therapies, including autologous hematopoietic stem cell transplantation, specifically for purging cancer cells from hematopoietic stem cells prior to transplantation.

Citing Articles

Innovative Approaches of Engineering Tumor-Targeting Bacteria with Different Therapeutic Payloads to Fight Cancer: A Smart Strategy of Disease Management.

Allemailem K Int J Nanomedicine. 2021; 16:8159-8184.

PMID: 34938075 PMC: 8687692. DOI: 10.2147/IJN.S338272.

Use of Bacteria in Cancer Therapy: Direct, Drug Delivery and Combination Approaches.

Badie F, Ghandali M, Tabatabaei S, Safari M, Khorshidi A, Shayestehpour M Front Oncol. 2021; 11:624759.

PMID: 33738260 PMC: 7960920. DOI: 10.3389/fonc.2021.624759.

Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium.

Lim D, Kim K, Kim H, Ko K, Song J, Choi J Oncotarget. 2017; 8(23):37550-37560.

PMID: 28473665 PMC: 5514929. DOI: 10.18632/oncotarget.17197.

References

Petty A, Wright S, Rewers-Felkins K, Yenderrozos M, Vorderstrasse B, Lindsey J . Targeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activity. Mol Cancer Ther. 2009; 8(8):2412-23. PMC: 2728173. DOI: 10.1158/1535-7163.MCT-09-0186. View

Prestrelski S, Arakawa T, Wu C, ONeal K, Westcott K, Narhi L . Solution structure and dynamics of epidermal growth factor and transforming growth factor alpha. J Biol Chem. 1992; 267(1):319-22. View

Roehm N, Rodgers G, Hatfield S, Glasebrook A . An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods. 1991; 142(2):257-65. DOI: 10.1016/0022-1759(91)90114-u. View

Siegall C, Fitzgerald D, Pastan I . Selective killing of tumor cells using EGF or TGF alpha-Pseudomonas exotoxin chimeric molecules. Semin Cancer Biol. 1990; 1(5):345-50. View

Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View

Wu M, Liebowitz D, Smith S, Williams S, Dolan M . Efficient expression of foreign genes in human CD34(+) hematopoietic precursor cells using electroporation. Gene Ther. 2001; 8(5):384-90. DOI: 10.1038/sj.gt.3301393. View

Jost L, Kirkwood J, Whiteside T . Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods. 1992; 147(2):153-65. DOI: 10.1016/s0022-1759(12)80003-2. View

Alajez N, Schmielau J, Alter M, Cascio M, Finn O . Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood. 2005; 105(12):4583-9. PMC: 1894994. DOI: 10.1182/blood-2004-10-3848. View

Siegall C, Xu Y, Chaudhary V, Adhya S, Fitzgerald D, Pastan I . Cytotoxic activities of a fusion protein comprised of TGF alpha and Pseudomonas exotoxin. FASEB J. 1989; 3(14):2647-52. DOI: 10.1096/fasebj.3.14.2556314. View

10.

Altman S, Randers L, Rao G . Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol Prog. 1993; 9(6):671-4. DOI: 10.1021/bp00024a017. View

11.

Wright S, Kilinski L, Talib S, Lowe K, Burnside J, Wu J . Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother. 2000; 23(1):2-10. DOI: 10.1097/00002371-200001000-00002. View

12.

Ross A, Cooper B, Lazarus H, Mackay W, Moss T, Ciobanu N . Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 1993; 82(9):2605-10. View

13.

Wright S, Rewers-Felkins K, Quinlin I, Eldridge P, Zorsky P, Klug P . Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med. 2002; 9(4):401-4. View

14.

Quinlin I, Burnside J, Dombrowski K, Phillips C, Dolby N, Wright S . Context of MUC1 epitope: immunogenicity. Oncol Rep. 2007; 17(2):453-6. DOI: 10.3892/or.17.2.453. View

15.

Barnd D, Lan M, METZGAR R, Finn O . Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A. 1989; 86(18):7159-63. PMC: 298015. DOI: 10.1073/pnas.86.18.7159. View

16.

Bode A, Ma W, Surh Y, Dong Z . Inhibition of epidermal growth factor-induced cell transformation and activator protein 1 activation by [6]-gingerol. Cancer Res. 2001; 61(3):850-3. View

17.

Rill D, Santana V, Roberts W, Nilson T, Bowman L, Krance R . Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994; 84(2):380-3. View

18.

Vennstrom L, Bysell C, Bjorkelund H, Lundqvist H, Andersson K . Real-time viability assay based on 51Cr retention in adherent cells. Biotechniques. 2008; 44(2):237-40. DOI: 10.2144/000112688. View

19.

Chiron M, Fryling C, Fitzgerald D . Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem. 1998; 272(50):31707-11. DOI: 10.1074/jbc.272.50.31707. View

20.

Wright S, Rewers-Felkins K, Quinlin I, Fogler W, Phillips C, Townsend M . MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest. 2008; 37(3):215-25. DOI: 10.1080/08820130801967874. View